Başer, Onur

Profile URL
https://hdl.handle.net/20.500.11779/2820
Name Variants
Job Title
Email Address
basero@mef.edu.tr
Main Affiliation
04. Faculty of Economics, Administrative and Social Sciences
Status
Former Staff
Website
ORCID ID
0000-0001-7447-5672
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
JUE-8293-2023

Research Topics

Domains
Social SciencesHealth Sciences
Fields
Economics, Econometrics and FinanceMedicine
Subfields
Economics and EconometricsCardiology and Cardiovascular MedicineRheumatologyInternal Medicine
Specific Research Areas
Health Systems, Economic Evaluations, Quality of Life
Atrial Fibrillation Management and Outcomes
Rheumatoid Arthritis Research and Therapies
Healthcare Policy and Management
Venous Thromboembolism Diagnosis and Management

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
44
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
0
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
0
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
0
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
10
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
0
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
1
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
2
Research Products
This researcher does not have a Scopus ID.
Documents

0

Citations

0

Go to WoS profile

Publication Collaboration

Affiliation Name Count
STATinMED (United States) 324
University of Michigan 256
Columbia University 71
City University of New York 57
Pfizer (United States) 49
1 / 40
Data obtained from OpenAlex
Scholarly Output

96

Articles

27

Views / Downloads

5019/822

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

403

Scopus Citation Count

449

Patents

0

Projects

0

WoS Citations per Publication

4.20

Scopus Citations per Publication

4.68

Open Access Source

22

Supervised Theses

0

JournalCount
Value in Health31
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting.18
International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress5
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting4
American Heart Association (AHA) Scientific Sessions 20152
Current Page: 1 / 8

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2014 - 2019922020 - 20214

Settings

Author of Publication: search.filters.isAuthorOfPublication.6960b0ec-7a84-4e87-a091-3b9e22c72a9c

Scholarly Output Search Results

Now showing 1 - 10 of 96
  • Conference Object
    Evaluating the Economic Burden and Health Care Utilization of Coronary Artery Disease in the Us Medi-Cal Population
    (2016) Zhang, Q; Zhao, Y; Keshishian, A; Xie, L; Yuce, H; Başer, Onur
    ...
  • Conference Object
  • Conference Object
    Spatial Distribution of the Total Number of Medical Devices in Turkey: a Classification Analysis
    (Elsevier Science Inc, 2016-11-01) Cinaroğlu, S.; Başer, Onur
    Objectives: The unbalanced distribution of medical technologies and devices between rural and urban areas is a major problem for developing countries including Turkey. After the establishment of Public Hospital Unions (PHUs) in Turkey, legislative changes were made to improve the autonomy of public hospitals. This study utilizes spatial analysis to assess the distribution of medical device use in Turkey using PHUs as a decision making unit. Methods: Data from the PHUs’ statistics year book for the year 2014 was assessed. The total number of PHUs is 89. A Hierarchical cluster analysis was performed to classify PHUs according to the total number of medical devices. The Euclidean distance measure and Wards methods were used in the analysis for classification. Results: Study results show that, in Turkey, PHUs were categorized into two clusters based on the total number of medical devices available. Regarding the spatial distribution of the clusters, the first cluster represents PHUs in rural areas, and the second represents PHUs located in urban areas of Turkey. PHUs representing large cities with high population density were included in one cluster, and all other PHUs were included in the second. Statistical test results indicated that the two clusters differ according to the total number of magnetic resonance imaging (MRI: t= -14.10, p< 0.01), computed tomography (CT) scan (t= -15.75, p< 0.01), mammography (t= -11.40, p< 0.01), ultrasonography (t= -14.62, p< 0.01), and electrocardiography (EKG; t= -12.29, p< 0.01) equipment available. Conclusions: It is advisable for health policy makers and health technology assessment authorities in Turkey to focus on the differences between rural and urban areas of the country when determining the need for medical devices.
  • Conference Object
    Trends in Prevalence and Incidence Rates of Type 2 Diabetes Mellitus in the Medicare Population
    (2015) Xie, L; Wang, Y; Tan, H; Ogbomo, A; Başer, Onur; Yuce H.
    ...
  • Conference Object
  • Conference Object
    Demographic and Clinical Characteristics of Patients With Polycythemia Vera (pv) in the Us Veterans Population
    (2016) Parasuraman S; Yu J; Paranagama D; Shrestha S; Wang L,; Başer, Onur
    ...
  • Article
    Citation - WoS: 15
    Citation - Scopus: 15
    Economic Outcomes in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate Plus Prednisone
    (Springer, 2020-02-28) Lechpammer, Stanislav; Ramaswamy, Krishnan; Wang, Li; Mardekian, Jack; George, Daniel J.; Sandin, Rickard; Schultz, Neil M.; Başer, Onur; Huang, Ahong
    Introduction: Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naı¨ve metastatic castration-resistant PC (mCRPC) treated with enzalutamide or abiraterone acetate plus prednisone (abiraterone). Methods: We performed a retrospective analysis on 3174 men (18 years or older) utilizing the Veterans Health Administration (VHA) database from 1 April 2014 to 31 March 2018. Men with mCRPC were included if they had at least one pharmacy claim for enzalutamide or abiraterone (first claim date = index date) following surgical or medical castration, had no chemotherapy treatment within 12 months prior to the index date, and had continuous VHA enrollment for at least 12 months pre- and post-index date. Men were followed until death, disenrollment, or end of study and were 1:1 propensity score matched (PSM). All-cause and PC-related resource use and costs per patient per month (PPPM) in the 12 months post index were compared between matched cohorts. Results: We identified 1229 men with mCRPC prescribed enzalutamide and 1945 prescribed abiraterone with mean ages of 74 and 73 years, respectively. After PSM, each cohort had 1160 patients. The enzalutamide cohort had fewer all-cause (2.51 vs 2.86; p\0.0001) and PC-related outpatient visits (0.86 vs 1.03; p\0.0001), with corresponding lower all-cause ($2588 vs $3115; p\0.0001) and PC-related ($1356 vs $1775; p\0.0001) PPPM outpatient costs compared with the abiraterone cohort. Allcause total costs (medical and pharmacy) PPPM ($8085 vs $9092; p = 0.0002) and PC-related total costs PPPM ($6321 vs $7280; p\0.0001) were significantly lower in the enzalutamide cohort compared with the abiraterone cohort. Conclusions: Enzalutamide-treated men with chemotherapy-naı ¨ve mCRPC had significantly lower resource utilization and healthcare costs compared with abiraterone-treated men. Plain Language Summary: Plain language summary available for this article.
  • Conference Object
  • Conference Object
    Evaluation of the Burden of Opioid Abuse Among Us Veteran Patients
    (2015) Başer, Onur; Ogbomo, A; Tan, H; Du, J; Xie L.
    ...
  • Conference Object
    Citation - WoS: 2
    Pcv58 - Long-Term Economic Burden Associated With Cardiovascular Events Among High-Risk Patients With Hyperlipidemia
    (Elsevier Science Inc, 2015-05-01) Fox, Kathleen M; Wang, Li; Gandra, S. R; Quek, R. G. W; Li, L; Başer, Onur
    Objectives: This study evaluated the economic burden associated with new cardiovascular events (CVEs) for 3 years post-CVE among high-risk patients diagnosedwith hyperlipidemia. Methods: A retrospective cohort study was conductedamong high-risk hyperlipidemic patients with and without a new CVE, using IMSLifeLink PharMetrics Plus data 01/01/2006-06/30/2012. CVEs included primary inpatient claims for myocardial infarction, unstable angina, ischemic stroke, transientischemic attack, revascularization and heart failure. Patients were assigned torisk cohorts based on history of CVE and coronary heart disease risk equivalent(CHD RE) condition. Propensity score matching was applied to compare healthcarecosts among patients with and without new CVEs, ranging from 1 month (acutephase) to 3 years post-CVE date. Results: A total of 21,482 matched patientswere included in the history of CVE cohort and 181,228 in the CHD RE cohort.Hyperlipidemic patients with new CVEs were, on average, aged 65-72 years, bothcohorts had 65.2% male and 74.7-84.4% had hypertension (most common baselinecomorbidity). Total costs per patient per month (PPPM) were significantly higheramong patients with versus without new CVEs during the acute phase (history ofCVE: $27,247 vs. $1,586; CHD RE: $30,742 vs. $914; p<0.0001) and remained higherduring years 1, 2 and 3, respectively, post-CVE among patients in the history of CVEcohort ($2,603 vs. $1,252; $2,055 vs. $1,191; $2,061 vs. $1,166, p<0.0001) and CHD REcohort ($1,926 vs. $844; $1,535 vs. $850; $1,475 vs. $853, p<0.0001). Significant costdifferences were observed between patients with and without new CVEs in bothcohorts, including inpatient, outpatient, emergency room and pharmacy visit costsPPPM, during 1-3 years post-CVE. Conclusions: Healthcare costs for high-riskpatients with new CVEs remained significantly higher than for matched patients without CVEs for up to 3 years post-CVE, imposing a significant economic burdenon U.S. commercial payers.